teduglutide

Details

Files

Generic Name:

Teduglutide

Project Status:

Complete

Therapeutic Area:

Short bowel syndrome

Manufacturer:

Shire Pharma Canada ULC/NPS Pharma Holdings Limited

Call for patient/clinician input open:

October 30, 2015

Brand Name:

Revestive

Project Line:

Reimbursement Review

Project Number:

SR0459-000

Call for patient/clinician input closed:

December 18, 2015

NOC Status at Filing:

Post NOC

Submission Type:

Initial

Indications:

Short Bowel Syndrome (SBS)

Recommendation Type:

Reimburse with clinical criteria and/or conditions

Final Recommendation:

July 27, 2016

Last Updated : October 30, 2015